Send to

Choose Destination
Psychopharmacol Bull. 1995;31(4):785-8.

Open-label trial of venlafaxine in adults with attention deficit disorder.

Author information

New York University Medical Center, NY, USA.


Antidepressants or stimulants are commonly used to treat attention deficit disorder (ADD). We report the results of an open-label trial of the recently marketed antidepressant venlafaxine in 16 adult patients with ADD. Patients were treated with venlafaxine (25 to 225 mg/day) for 8 weeks. Four patients discontinued treatment within the first week because of sedation, agitation, or nausea. In the remaining 12 patients, venlafaxine treatment decreased ADD ratings by almost half.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center